Cipla Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Cipla Limited Pharmaceutical Export Portfolio Dataset — 98 Products, $1.1B FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla Limited — Pharmaceutical Exporter Profile (2026) | 98 Products, $1.1B Trade | TransData Nexus

Cipla Limited

Indian Pharmaceutical Exporter · Respiratory Specialist · $1.1B Total Trade · DGFT Verified

Cipla Limited is an Indian pharmaceutical exporter with a total trade value of $1.1B across 98 products in 26 therapeutic categories. Based on 29,033 verified export shipments from Indian Customs (DGFT) records, Cipla Limited is the #1 Indian exporter in 18 products including Fluticasone, Amlodipine, Salbutamol. Top exports include Fluticasone ($133.2M), Amlodipine ($101.8M), Salbutamol ($100.3M).

Cipla Limited — Export Portfolio & Destination Treemap

Cipla Limited pharmaceutical export portfolio — 98 products across 26 therapeutic categories. Source: Indian Customs (DGFT).

Who is Cipla Limited? — Company Overview & Market Position

Cipla Limited, established in 1935 by Khwaja Abdul Hamied, is a leading Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company specializes in the development, manufacturing, and distribution of a wide range of pharmaceutical products, including generic and branded generic medicines, vaccines, and active pharmaceutical ingredients (APIs). Cipla's therapeutic portfolio spans areas such as respiratory, cardiovascular, oncology, and infectious diseases.

As of March 2024, Cipla employed approximately 27,764 individuals. The company's equity shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE), where it is a constituent of the BSE SENSEX and the CNX Nifty indices. Additionally, Cipla's Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.

What Does Cipla Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Fluticasone$133.2M 2Amlodipine

Product Portfolio — Top 30 by Export Value

Cipla Limited exports 98 pharmaceutical products across 26 therapeutic categories. Market leader (#1 exporter) in 18 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fluticasone	Respiratory	$133.2M	2,663	65.6%	1
2	Amlodipine	Cardiovascular	$101.8M	2,036	0.9%	1
3	Salbutamol	Respiratory	$100.3M	2,828	67.4%	1
4	Telmisartan	Cardiovascular	$81.0M	1,619	0.7%	1
5	Salmeterol	Respiratory	$55.7M	1,265	76.5%	1
6	Budesonide	Respiratory	$53.0M	1,060	27.8%	1
7	Dolutegravir	Antiviral & HIV Medications	$47.5M	949	1.1%	4
8	Omeprazole	Gastrointestinal	$44.0M	879	6.9%	2
9	Tenofovir	Antiviral & HIV Medications	$40.4M	808	0.9%	6
10	Esomeprazole	Gastrointestinal	$30.6M	611	6.7%	2
11	Meloxicam	Analgesics & Antipyretics	$28.7M	889	14.4%	2
12	Sertraline	CNS & Psychiatric	$27.5M	550	4.9%	1
13	Formoterol	Respiratory	$25.3M	572	44.1%	1
14	Sodium	Nutritional Supplements	$22.2M	738	6.1%	4
15	Magnesium	Vitamins & Supplements	$22.0M	440	6.1%	2
16	Diclofenac	Analgesics & Antipyretics	$20.9M	1,059	5.7%	4
17	Ipratropium	Respiratory	$20.1M	402	35.2%	1
18	Metoprolol	Cardiovascular	$15.9M	319	2.0%	2
19	Calcium	Vitamins & Supplements	$13.9M	613	1.5%	8
20	Fexofenadine	Antihistamines & Allergy	$13.6M	921	12.4%	3
21	Celecoxib	Analgesics & Antipyretics	$12.2M	384	9.1%	4
22	Lansoprazole	Gastrointestinal	$11.3M	267	3.9%	5
23	Methotrexate	Immunosuppressants	$10.8M	217	31.1%	1
24	Potassium	Nutritional Supplements	$10.6M	211	1.6%	11
25	Cephalexin	Antibiotics	$9.2M	184	2.6%	5
26	Losartan	Cardiovascular	$9.2M	184	3.1%	3
27	Azithromycin	Antibiotics	$8.4M	208	4.6%	5
28	Ras	Ayurvedic & Herbal Products	$8.3M	166	2.7%	1
29	Citalopram	CNS & Psychiatric	$8.2M	239	3.2%	8
30	Escitalopram	CNS & Psychiatric	$7.9M	218	4.0%	7

Cipla Limited exports 98 pharmaceutical products across 26 therapeutic categories with a total export value of $1.1B. The company is the #1 Indian exporter in 18 products: Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol and 6 more. The top category is Respiratory (35.3% of portfolio), followed by Cardiovascular (19.4%), reflecting a diversified portfolio where the top 5 products account for only 41.9% of total value.

Showing top 30 of 98 products. Contact us for complete data.

Cipla Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Cipla operates 47 manufacturing facilities across the globe, including 34 units in India. These facilities are strategically located in cities such as Mumbai, Hyderabad, and Ahmedabad, enabling efficient production and distribution. The company's manufacturing plants are cGMP compliant and approved by major international regulatory agencies, including the US FDA, MHRA (UK), TGA (Australia), and WHO.

3Key Leadership

The leadership team at Cipla is headed by Managing Director and Global Chief Executive Officer, Umang Vohra, who has been with the company since 2015. Other key executives include Ashish Adukia, serving as the Global Chief Financial Officer, and Achin Gupta, the Global Chief Operating Officer. Additionally, Sneha Hiranandani holds the position of Chief Information Officer.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Cipla Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Cipla has a significant presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company has received approvals for various products from regulatory bodies like the US FDA, MHRA, and TGA, facilitating market access in these regions. Cipla's manufacturing facilities are cGMP compliant and have been inspected and approved by these agencies, ensuring adherence to international quality standards.

2Emerging Markets

Cipla has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are available in over 80 countries, with a strong presence in regions such as South Africa and the Middle East. Cipla's commitment to affordability and accessibility has enabled it to penetrate these markets effectively.

3Geographic Strategy

Cipla's geographic strategy focuses on diversification to mitigate concentration risk. The company has established a presence in over 80 countries, balancing its operations across developed and emerging markets. This approach allows Cipla to leverage growth opportunities globally while managing risks associated with overdependence on a single market.

Cipla Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Cipla's manufacturing facilities are registered with the US FDA, and the company has received approvals for various Abbreviated New Drug Applications (ANDAs). The facilities have undergone inspections by the FDA, ensuring compliance with stringent quality standards. Cipla's commitment to quality is further demonstrated by its adherence to cGMP guidelines, facilitating the approval of its products in the US market.

2WHO & EU GMP

Cipla's manufacturing facilities hold certifications from the World Health Organization (WHO) and the European Union's Good Manufacturing Practice (EU GMP). These certifications affirm the company's compliance with international quality standards, enabling it to supply products to various global markets.

3CDSCO & Indian Regulatory

In India, Cipla's manufacturing facilities are licensed by the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulatory requirements. Cipla also obtains export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT) for its export shipments.

Cipla Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Cipla operates in a competitive landscape with key players such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Lupin Limited. In the respiratory segment, Cipla holds a 65.6% market share in Fluticasone, 67.4% in Salbutamol, and 76.5% in Salmeterol, indicating strong leadership. However, in the cardiovascular segment, Cipla's market share is relatively low, with 0.9% in Amlodipine and 0.7% in Telmisartan, suggesting opportunities for growth.

2Key Differentiators

Cipla's key differentiators include its extensive product portfolio across 26 therapeutic categories, strong presence in the respiratory segment, and commitment to affordability and accessibility. The company's focus on high-quality manufacturing, evidenced by cGMP compliance and international certifications, further distinguishes it in the market.

3Strategic Position

Cipla's strategic direction encompasses a balanced approach between generics, specialty medicines, biosimilars, and contract development and manufacturing organization (CDMO) services. The company's focus on expanding its presence in emerging markets and enhancing its product portfolio aligns with its future outlook of sustainable growth and global reach.

Buyer Due Diligence Brief — Evaluating Cipla Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Cipla has a strong track record in manufacturing and exporting pharmaceutical products, with a total export value of $1.1 billion USD and 29,033 shipments across 98 products in 26 therapeutic categories. The company's consistent delivery of high-quality products and adherence to international standards underscore its reliability as a supplier.

2Certifications to Verify

Importers should verify Cipla's certifications, including FDA facility registrations, WHO prequalification, EU GMP certificates, and ISO certifications. These can be verified through official regulatory agency websites or by contacting Cipla directly.

3Due Diligence Checklist

Verify Cipla's FDA facility registrations and approved ANDAs.
Confirm WHO prequalification and EU GMP certificates.

Frequently Asked Questions — Cipla Limited

How many pharmaceutical products does Cipla Limited export from India?

Cipla Limited exports 98 finished pharmaceutical formulations across 26 therapeutic categories from India.

What is Cipla Limited's total pharmaceutical export value?

Cipla Limited's total pharmaceutical export value is $1.1 billion USD, based on data from 2022 to 2026.

What are Cipla Limited's top exported pharmaceutical formulations?

Cipla Limited's top exported pharmaceutical formulations include Fluticasone ($133.2M, 65.6% market share), Amlodipine ($101.8M, 0.9% market share), Salbutamol ($100.3M, 67.4% market share), Telmisartan ($81.0M, 0.7% market share), and Salmeterol ($55.7M, 76.5% market share).

Which therapeutic categories does Cipla Limited specialize in?

Cipla Limited specializes in therapeutic categories such as Respiratory (35.3% of exports), Cardiovascular (19.4%), and Gastrointestinal (8.4%).

Is Cipla Limited FDA approved for pharmaceutical exports?

Yes, Cipla Limited is FDA approved for pharmaceutical exports. The company has filed 503 Drug Master Files (DMFs) and 270 Abbreviated New Drug Applications (ANDAs) with the FDA, with 333 approvals as of March 31, 2024.

What countries does Cipla Limited export pharmaceuticals to?

Cipla Limited exports pharmaceuticals to multiple countries, including the USA, Europe, South Africa, and various emerging markets. The company has filed regulatory dossiers and received approvals across these regions.

Get Full Cipla Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.